aTyr Pharma, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ATYR Nasdaq 2834 atyrpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for aTyr Pharma, Inc.

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026 - Jul 15th, 2026 6:00 am
What It Means To Hold Moderna Stock In A Crash - Jul 13th, 2026 7:12 am
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing - Jun 26th, 2026 6:35 am
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th - Jun 23rd, 2026 6:35 am
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update - May 15th, 2026 6:00 am
aTyr Pharma to Participate in Upcoming Investor Conferences - May 13th, 2026 2:01 pm
aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial - May 11th, 2026 6:09 pm
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting - May 11th, 2026 2:01 pm
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - Apr 8th, 2026 11:00 am
aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting - Mar 12th, 2026 6:03 am
Atyr Pharma: Q4 Earnings Snapshot - Mar 5th, 2026 2:10 pm
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update - Mar 5th, 2026 2:01 pm
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 20th, 2026 2:01 pm
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference - Feb 18th, 2026 6:00 am
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis - Feb 3rd, 2026 6:00 am
Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Deliver On Growth Plans? - Jan 11th, 2026 6:51 am
aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference - Nov 10th, 2025 6:00 am
Atyr Pharma: Q3 Earnings Snapshot - Nov 6th, 2025 2:48 pm
aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update - Nov 6th, 2025 2:01 pm
Independent Director of aTyr Pharma Paul Schimmel Buys 91% More Shares - Oct 12th, 2025 6:31 am